
Global Filgrastim and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Filgrastim and Biosimilars market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Filgrastim and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Filgrastim and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Filgrastim and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Filgrastim and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Filgrastim and Biosimilars include Changchun GeneScience Pharmaceutical, CSPC Baike Biopharma, Shanghai Sunway Biotech, Amoytop Biotech, Qilu Pharmaceutical, Kexing Biopharm, Jiangsu Wuzhong Pharmaceutical, North China Pharmaceutical and Hangzhou Jiuyuan Gene Engineering, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Filgrastim and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Filgrastim and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Filgrastim and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Filgrastim and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Filgrastim and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Filgrastim and Biosimilars sales, projected growth trends, production technology, application and end-user industry.
Filgrastim and Biosimilars Segment by Company
Changchun GeneScience Pharmaceutical
CSPC Baike Biopharma
Shanghai Sunway Biotech
Amoytop Biotech
Qilu Pharmaceutical
Kexing Biopharm
Jiangsu Wuzhong Pharmaceutical
North China Pharmaceutical
Hangzhou Jiuyuan Gene Engineering
Harbin Pharmaceutical Group
Chengdu Institute of Biological Products
SL Pharm
Teva
Tanvex BioPharma
Sandoz
Pfizer
Kashiv BioSciences
Amgen
Filgrastim and Biosimilars Segment by Type
Single-use Vials
Prefilled Syringes
Filgrastim and Biosimilars Segment by Application
Hospital and Clinic
Pharmacy
Other
Filgrastim and Biosimilars Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Filgrastim and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Filgrastim and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Filgrastim and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Filgrastim and Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Filgrastim and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Filgrastim and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Filgrastim and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Filgrastim and Biosimilars market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Filgrastim and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Filgrastim and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Filgrastim and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Filgrastim and Biosimilars is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Filgrastim and Biosimilars include Changchun GeneScience Pharmaceutical, CSPC Baike Biopharma, Shanghai Sunway Biotech, Amoytop Biotech, Qilu Pharmaceutical, Kexing Biopharm, Jiangsu Wuzhong Pharmaceutical, North China Pharmaceutical and Hangzhou Jiuyuan Gene Engineering, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Filgrastim and Biosimilars, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Filgrastim and Biosimilars, also provides the sales of main regions and countries. Of the upcoming market potential for Filgrastim and Biosimilars, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Filgrastim and Biosimilars sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Filgrastim and Biosimilars market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Filgrastim and Biosimilars sales, projected growth trends, production technology, application and end-user industry.
Filgrastim and Biosimilars Segment by Company
Changchun GeneScience Pharmaceutical
CSPC Baike Biopharma
Shanghai Sunway Biotech
Amoytop Biotech
Qilu Pharmaceutical
Kexing Biopharm
Jiangsu Wuzhong Pharmaceutical
North China Pharmaceutical
Hangzhou Jiuyuan Gene Engineering
Harbin Pharmaceutical Group
Chengdu Institute of Biological Products
SL Pharm
Teva
Tanvex BioPharma
Sandoz
Pfizer
Kashiv BioSciences
Amgen
Filgrastim and Biosimilars Segment by Type
Single-use Vials
Prefilled Syringes
Filgrastim and Biosimilars Segment by Application
Hospital and Clinic
Pharmacy
Other
Filgrastim and Biosimilars Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Filgrastim and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Filgrastim and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Filgrastim and Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Filgrastim and Biosimilars market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Filgrastim and Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Filgrastim and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Filgrastim and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
192 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Filgrastim and Biosimilars Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Filgrastim and Biosimilars Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Filgrastim and Biosimilars Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Filgrastim and Biosimilars Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Filgrastim and Biosimilars Market Dynamics
- 2.1 Filgrastim and Biosimilars Industry Trends
- 2.2 Filgrastim and Biosimilars Industry Drivers
- 2.3 Filgrastim and Biosimilars Industry Opportunities and Challenges
- 2.4 Filgrastim and Biosimilars Industry Restraints
- 3 Filgrastim and Biosimilars Market by Manufacturers
- 3.1 Global Filgrastim and Biosimilars Revenue by Manufacturers (2020-2025)
- 3.2 Global Filgrastim and Biosimilars Sales by Manufacturers (2020-2025)
- 3.3 Global Filgrastim and Biosimilars Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Filgrastim and Biosimilars Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Filgrastim and Biosimilars Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Filgrastim and Biosimilars Manufacturers, Product Type & Application
- 3.7 Global Filgrastim and Biosimilars Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Filgrastim and Biosimilars Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Filgrastim and Biosimilars Players Market Share by Revenue in 2024
- 3.8.3 2024 Filgrastim and Biosimilars Tier 1, Tier 2, and Tier 3
- 4 Filgrastim and Biosimilars Market by Type
- 4.1 Filgrastim and Biosimilars Type Introduction
- 4.1.1 Single-use Vials
- 4.1.2 Prefilled Syringes
- 4.2 Global Filgrastim and Biosimilars Sales by Type
- 4.2.1 Global Filgrastim and Biosimilars Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Filgrastim and Biosimilars Sales by Type (2020-2031)
- 4.2.3 Global Filgrastim and Biosimilars Sales Market Share by Type (2020-2031)
- 4.3 Global Filgrastim and Biosimilars Revenue by Type
- 4.3.1 Global Filgrastim and Biosimilars Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Filgrastim and Biosimilars Revenue by Type (2020-2031)
- 4.3.3 Global Filgrastim and Biosimilars Revenue Market Share by Type (2020-2031)
- 5 Filgrastim and Biosimilars Market by Application
- 5.1 Filgrastim and Biosimilars Application Introduction
- 5.1.1 Hospital and Clinic
- 5.1.2 Pharmacy
- 5.1.3 Other
- 5.2 Global Filgrastim and Biosimilars Sales by Application
- 5.2.1 Global Filgrastim and Biosimilars Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Filgrastim and Biosimilars Sales by Application (2020-2031)
- 5.2.3 Global Filgrastim and Biosimilars Sales Market Share by Application (2020-2031)
- 5.3 Global Filgrastim and Biosimilars Revenue by Application
- 5.3.1 Global Filgrastim and Biosimilars Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Filgrastim and Biosimilars Revenue by Application (2020-2031)
- 5.3.3 Global Filgrastim and Biosimilars Revenue Market Share by Application (2020-2031)
- 6 Global Filgrastim and Biosimilars Sales by Region
- 6.1 Global Filgrastim and Biosimilars Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Filgrastim and Biosimilars Sales by Region (2020-2031)
- 6.2.1 Global Filgrastim and Biosimilars Sales by Region (2020-2025)
- 6.2.2 Global Filgrastim and Biosimilars Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Filgrastim and Biosimilars Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Filgrastim and Biosimilars Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Filgrastim and Biosimilars Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Filgrastim and Biosimilars Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Filgrastim and Biosimilars Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Filgrastim and Biosimilars Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Filgrastim and Biosimilars Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Filgrastim and Biosimilars Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Filgrastim and Biosimilars Revenue by Region
- 7.1 Global Filgrastim and Biosimilars Revenue by Region
- 7.1.1 Global Filgrastim and Biosimilars Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Filgrastim and Biosimilars Revenue by Region (2020-2025)
- 7.1.3 Global Filgrastim and Biosimilars Revenue by Region (2026-2031)
- 7.1.4 Global Filgrastim and Biosimilars Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Filgrastim and Biosimilars Revenue (2020-2031)
- 7.2.2 North America Filgrastim and Biosimilars Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Filgrastim and Biosimilars Revenue (2020-2031)
- 7.3.2 Europe Filgrastim and Biosimilars Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Filgrastim and Biosimilars Revenue (2020-2031)
- 7.4.2 Asia-Pacific Filgrastim and Biosimilars Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Filgrastim and Biosimilars Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Filgrastim and Biosimilars Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Changchun GeneScience Pharmaceutical
- 8.1.1 Changchun GeneScience Pharmaceutical Comapny Information
- 8.1.2 Changchun GeneScience Pharmaceutical Business Overview
- 8.1.3 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Changchun GeneScience Pharmaceutical Filgrastim and Biosimilars Product Portfolio
- 8.1.5 Changchun GeneScience Pharmaceutical Recent Developments
- 8.2 CSPC Baike Biopharma
- 8.2.1 CSPC Baike Biopharma Comapny Information
- 8.2.2 CSPC Baike Biopharma Business Overview
- 8.2.3 CSPC Baike Biopharma Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 CSPC Baike Biopharma Filgrastim and Biosimilars Product Portfolio
- 8.2.5 CSPC Baike Biopharma Recent Developments
- 8.3 Shanghai Sunway Biotech
- 8.3.1 Shanghai Sunway Biotech Comapny Information
- 8.3.2 Shanghai Sunway Biotech Business Overview
- 8.3.3 Shanghai Sunway Biotech Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Shanghai Sunway Biotech Filgrastim and Biosimilars Product Portfolio
- 8.3.5 Shanghai Sunway Biotech Recent Developments
- 8.4 Amoytop Biotech
- 8.4.1 Amoytop Biotech Comapny Information
- 8.4.2 Amoytop Biotech Business Overview
- 8.4.3 Amoytop Biotech Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Amoytop Biotech Filgrastim and Biosimilars Product Portfolio
- 8.4.5 Amoytop Biotech Recent Developments
- 8.5 Qilu Pharmaceutical
- 8.5.1 Qilu Pharmaceutical Comapny Information
- 8.5.2 Qilu Pharmaceutical Business Overview
- 8.5.3 Qilu Pharmaceutical Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 Qilu Pharmaceutical Filgrastim and Biosimilars Product Portfolio
- 8.5.5 Qilu Pharmaceutical Recent Developments
- 8.6 Kexing Biopharm
- 8.6.1 Kexing Biopharm Comapny Information
- 8.6.2 Kexing Biopharm Business Overview
- 8.6.3 Kexing Biopharm Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Kexing Biopharm Filgrastim and Biosimilars Product Portfolio
- 8.6.5 Kexing Biopharm Recent Developments
- 8.7 Jiangsu Wuzhong Pharmaceutical
- 8.7.1 Jiangsu Wuzhong Pharmaceutical Comapny Information
- 8.7.2 Jiangsu Wuzhong Pharmaceutical Business Overview
- 8.7.3 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Jiangsu Wuzhong Pharmaceutical Filgrastim and Biosimilars Product Portfolio
- 8.7.5 Jiangsu Wuzhong Pharmaceutical Recent Developments
- 8.8 North China Pharmaceutical
- 8.8.1 North China Pharmaceutical Comapny Information
- 8.8.2 North China Pharmaceutical Business Overview
- 8.8.3 North China Pharmaceutical Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 North China Pharmaceutical Filgrastim and Biosimilars Product Portfolio
- 8.8.5 North China Pharmaceutical Recent Developments
- 8.9 Hangzhou Jiuyuan Gene Engineering
- 8.9.1 Hangzhou Jiuyuan Gene Engineering Comapny Information
- 8.9.2 Hangzhou Jiuyuan Gene Engineering Business Overview
- 8.9.3 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 Hangzhou Jiuyuan Gene Engineering Filgrastim and Biosimilars Product Portfolio
- 8.9.5 Hangzhou Jiuyuan Gene Engineering Recent Developments
- 8.10 Harbin Pharmaceutical Group
- 8.10.1 Harbin Pharmaceutical Group Comapny Information
- 8.10.2 Harbin Pharmaceutical Group Business Overview
- 8.10.3 Harbin Pharmaceutical Group Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 Harbin Pharmaceutical Group Filgrastim and Biosimilars Product Portfolio
- 8.10.5 Harbin Pharmaceutical Group Recent Developments
- 8.11 Chengdu Institute of Biological Products
- 8.11.1 Chengdu Institute of Biological Products Comapny Information
- 8.11.2 Chengdu Institute of Biological Products Business Overview
- 8.11.3 Chengdu Institute of Biological Products Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Chengdu Institute of Biological Products Filgrastim and Biosimilars Product Portfolio
- 8.11.5 Chengdu Institute of Biological Products Recent Developments
- 8.12 SL Pharm
- 8.12.1 SL Pharm Comapny Information
- 8.12.2 SL Pharm Business Overview
- 8.12.3 SL Pharm Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.12.4 SL Pharm Filgrastim and Biosimilars Product Portfolio
- 8.12.5 SL Pharm Recent Developments
- 8.13 Teva
- 8.13.1 Teva Comapny Information
- 8.13.2 Teva Business Overview
- 8.13.3 Teva Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.13.4 Teva Filgrastim and Biosimilars Product Portfolio
- 8.13.5 Teva Recent Developments
- 8.14 Tanvex BioPharma
- 8.14.1 Tanvex BioPharma Comapny Information
- 8.14.2 Tanvex BioPharma Business Overview
- 8.14.3 Tanvex BioPharma Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.14.4 Tanvex BioPharma Filgrastim and Biosimilars Product Portfolio
- 8.14.5 Tanvex BioPharma Recent Developments
- 8.15 Sandoz
- 8.15.1 Sandoz Comapny Information
- 8.15.2 Sandoz Business Overview
- 8.15.3 Sandoz Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.15.4 Sandoz Filgrastim and Biosimilars Product Portfolio
- 8.15.5 Sandoz Recent Developments
- 8.16 Pfizer
- 8.16.1 Pfizer Comapny Information
- 8.16.2 Pfizer Business Overview
- 8.16.3 Pfizer Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.16.4 Pfizer Filgrastim and Biosimilars Product Portfolio
- 8.16.5 Pfizer Recent Developments
- 8.17 Kashiv BioSciences
- 8.17.1 Kashiv BioSciences Comapny Information
- 8.17.2 Kashiv BioSciences Business Overview
- 8.17.3 Kashiv BioSciences Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.17.4 Kashiv BioSciences Filgrastim and Biosimilars Product Portfolio
- 8.17.5 Kashiv BioSciences Recent Developments
- 8.18 Amgen
- 8.18.1 Amgen Comapny Information
- 8.18.2 Amgen Business Overview
- 8.18.3 Amgen Filgrastim and Biosimilars Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.18.4 Amgen Filgrastim and Biosimilars Product Portfolio
- 8.18.5 Amgen Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Filgrastim and Biosimilars Value Chain Analysis
- 9.1.1 Filgrastim and Biosimilars Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Filgrastim and Biosimilars Production Mode & Process
- 9.2 Filgrastim and Biosimilars Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Filgrastim and Biosimilars Distributors
- 9.2.3 Filgrastim and Biosimilars Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.